Skip to main content
. 2013 Jun 20;17(3):R114. doi: 10.1186/cc12786

Figure 8.

Figure 8

Effect of post-treatment with imatinib or nilotinib. (A) Representative images of H&E-stained lung sections from six experimental groups. (B) Number of inflammatory cells in bronchoalveolar lavage (BAL) fluid. (C) Albumin level in BAL fluid. (D) Myeloperoxidase (MPO) analysis. LPS, lipopolysaccharide; C, cyclophosphamide; I, imatinib; N, nilotinib. *P <0.05 and **P <0.01 for C + LPS versus C + LPS + I/N (post); #P <0.05 and ##P <0.01 for C + LPS + I/N versus C + LPS + I/N (post). Post, post-induction of LPS.